A compound that is effective as a diagnostic imaging probe that targets amyloid including is represented by the following formula (1), or salt thereof:
wherein R
1
is a radioactive halogen substituent, A
1
and A
2
independently represent CH or N. A diagnostic agent for Alzheimer's disease includes the compound represented by the above formula or a salt thereof. The above compound and the above diagnostic agent for Alzheimer's disease transfer into brain after administration, and indicate good accumulation on amyloid deposited in the brain.
In this study, we synthesized of a series of 2phenyl- and 2-pyridyl-imidazo[1,2-a]pyridine derivatives and examine their suitability as novel probes for single-photon emission computed tomography (SPECT)-based imaging of beta-amyloid (A beta). Among the 11 evaluated compounds, 10 showed moderate affinity to A beta(1-42) aggregates, exhibiting half-maximal inhibitory concentrations (IC50) of 14.7 +/- 6.07-87.6 +/- 39.8 nM. In vitro autoradiography indicated that 1231 labeled triazole-substituted derivatives displayed highly selective binding to A beta plaques in the hippocampal region of Alzheimer's disease (AD)-affected brain. Moreover, biodistribution studies performed on normal rats demonstrated that all I-123-labeled probes featured high initial uptake into the brain followed by a rapid washout and were thus well suited for imaging A beta plaques, with the highest selectivity observed for a 1H-1,2,3-triazole-substituted 2-pyridyl-imidazopyridine derivative, [I-123]ABC577. This compound showed good kinetics in rat brain as well as moderate in vivo stability in rats and is thus a promising SPECT imaging probe for AD in clinical settings.
US9149546B2
申请人:——
公开号:US9149546B2
公开(公告)日:2015-10-06
[EN] NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID<br/>[FR] NOUVEAU COMPOSÉ AYANT UNE AFFINITÉ POUR LA SUBSTANCE AMYLOÏDE